Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.44 PLN | -4.81% | +4.89% | -20.82% |
05-17 | Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-22 | Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.82% | 69.7M | |
+9.38% | 114B | |
+13.00% | 107B | |
-6.99% | 22.22B | |
-1.75% | 21.28B | |
-4.45% | 18.8B | |
-5.89% | 17.51B | |
-39.36% | 17.17B | |
+7.29% | 14.14B | |
+35.20% | 12.2B |
- Stock Market
- Equities
- MOC Stock
- News Molecure S.A.
- Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment